Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.
You may also be interested in...
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
FDA To Centocor: Show Me The REMS
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
J&J’s Stelara Beats Enbrel In Psoriasis
New survey shows doctors are warming to another rival, Humira.